Medivation (MDVN) Decline Tied to J&J (JNJ) / Aragon Deal
Tweet
Share
E-mailGet Alerts MDVN Hot Sheet
Join SI Premium – FREE
Shares of Medivation (Nasdaq: MDVN) declined on Monday. The fall is tied to news Johnson & Johnson (NYSE: JNJ) signed a definitive agreement to acquire Aragon Pharmaceuticals, Inc., a privately-held, pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers.
The acquisition includes Aragon's androgen receptor antagonist program. Aragon's lead product candidate is a second generation androgen receptor signaling inhibitor, ARN-509, in Phase 2 development for castration resistant prostate cancer (CRPC).
Investors could see increased competition for Medivation's prostate cancer drug, Xtandi.
The acquisition includes Aragon's androgen receptor antagonist program. Aragon's lead product candidate is a second generation androgen receptor signaling inhibitor, ARN-509, in Phase 2 development for castration resistant prostate cancer (CRPC).
Investors could see increased competition for Medivation's prostate cancer drug, Xtandi.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
- Premarket movers: Crypto stocks rally, Ross Stores jump on upbeat forecast
- Is the global equity rally broadening? UBS weighs in
Create E-mail Alert Related Categories
General News, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
